BioSpace News Archive

Omnia Medical announced that the Patent Trial and Appeal Board of the US Patent and Trademark Office on Thursday September 20th granted institution in IPR2023-00625.

Cognitive Research Corporation (“CRC”) is pleased to announce that clinical research industry veteran, Dr. Tom Zoda has been appointed as Chief Executive Officer and a member of the Board of Directors effective immediately.

OPKO Health, Inc. announced the closing of its previously announced private offering of $230.0 million aggregate principal amount of its Convertible Senior Notes due 2029, which amount includes the full exercise of the initial purchaser’s option to purchase an additional $30.0 million aggregate principal amount of the Notes.

Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 26th Annual Needham Growth Conference in New York, NY, on Thursday, January 18, 2024, which includes a presentation beginning at 10:15 am ET.

Lirum Therapeutics, Inc. announced that management is participating in the 13th Annual LifeSci Partners Corporate Access Event, which is taking place January 8-10, 2024 at the Beacon Grand Hotel in San Francisco, California during J.P. Morgan week.

LinkedUp Bioscience and TianTi Biotherapeutics are pleased to announce the resolution of the lawsuit brought by Adimab, LLC, and related parties.

Shanghai Junshi Biosciences Co., Ltd announced the publication of results from TORCHLIGHT, a randomized, double-blind, placebo-controlled phase 3 study comparing the efficacy and safety of toripalimab versus placebo, in combination with nab-paclitaxel for patients with newly diagnosed metastatic or recurrent locally advanced triple-negative breast cancer in Nature Medicine.

Teva Pharmaceutical Industries Ltd. announced the successful completion of the enrollment in the EU and US of the anticipated 640 participants of the ongoing Phase 3 clinical trial of mdc-TJK (TEV-44749) at the J.P. Morgan Healthcare Conference.

Nyxoah SA announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2023.

C4 Therapeutics, Inc. announced 2024 priorities to execute against its strategic plan to leverage the benefits of targeted protein degradation across drug discovery and clinical development to create and deliver breakthrough therapies for patients.